Stratum Biosciences develops SkinSync™, an AI-powered skin biology discovery platform that mines a biobank of over 200,000 real tissue samples to identify novel biomarkers and targets for skin products. The company aims to translate discoveries into composition-of-matter actives and optimized formulations with improved delivery and bioavailability. Stratum has validated its platform through partnerships with global consumer packaged goods leaders and subsidiaries to advance products addressing hyperpigmentation, skin longevity, and eczema. Founded in 2024 by dermatologist Dr. Ross Lane Pearlman and dermatopathologist Dr. Buu Duong, Stratum is a resident company at Johnson & Johnson’s JLABs@NYC and participates in NVIDIA’s Inception program to access advanced computing resources. Following its $2M seed raise, the company is focused on scaling R&D, expanding partnerships, and building a pipeline of IP-backed ingredient and formulation technologies.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026